185 related articles for article (PubMed ID: 38331768)
1. Quantified pathway mutations associate epithelial-mesenchymal transition and immune escape with poor prognosis and immunotherapy resistance of head and neck squamous cell carcinoma.
Huang Y; Liu H; Liu B; Chen X; Li D; Xue J; Li N; Zhu L; Yang L; Xiao J; Liu C
BMC Med Genomics; 2024 Feb; 17(1):49. PubMed ID: 38331768
[TBL] [Abstract][Full Text] [Related]
2. Construction and validation of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in laryngeal squamous cell carcinoma.
Wang X; Pan Y; Ou Y; Duan T; Zou Y; Zhou X
World J Surg Oncol; 2022 May; 20(1):164. PubMed ID: 35606755
[TBL] [Abstract][Full Text] [Related]
3. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
4. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL
Front Immunol; 2022; 13():969034. PubMed ID: 36466881
[TBL] [Abstract][Full Text] [Related]
5. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
[TBL] [Abstract][Full Text] [Related]
6. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
[No Abstract] [Full Text] [Related]
7.
Wu L; Liu Y; Deng W; Wu T; Bu L; Chen L
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629087
[TBL] [Abstract][Full Text] [Related]
8. Construction of an m6A-related lncRNA pair prognostic signature and prediction of the immune landscape in head and neck squamous cell carcinoma.
Zhou C; Wang S; Shen Z; Shen Y; Li Q; Shen Y; Huang J; Deng H; Ye D; Zhan G; Li J
J Clin Lab Anal; 2022 Jan; 36(1):e24113. PubMed ID: 34783061
[TBL] [Abstract][Full Text] [Related]
9. A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer.
Schinke H; Shi E; Lin Z; Quadt T; Kranz G; Zhou J; Wang H; Hess J; Heuer S; Belka C; Zitzelsberger H; Schumacher U; Genduso S; Riecken K; Gao Y; Wu Z; Reichel CA; Walz C; Canis M; Unger K; Baumeister P; Pan M; Gires O
Mol Cancer; 2022 Sep; 21(1):178. PubMed ID: 36076232
[TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Biomarkers for Predicting Prognosis and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma Based on ceRNA Network and Immune Infiltration Analysis.
Guo Y; Pan WK; Wang ZW; Su WH; Xu K; Jia H; Chen J
Biomed Res Int; 2021; 2021():4532438. PubMed ID: 34917682
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of immune cell infiltration and significant genes in head and neck squamous cell carcinoma.
Zhang S; Zhang W; Zhang J
Oral Oncol; 2022 Mar; 126():105755. PubMed ID: 35144208
[TBL] [Abstract][Full Text] [Related]
12. A novel neutrophil extracellular trap signature to predict prognosis and immunotherapy response in head and neck squamous cell carcinoma.
Li Q; Chen W; Li Q; Mao J; Chen X
Front Immunol; 2022; 13():1019967. PubMed ID: 36225931
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma.
Jung AR; Jung CH; Noh JK; Lee YC; Eun YG
Sci Rep; 2020 Feb; 10(1):3652. PubMed ID: 32107458
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
[TBL] [Abstract][Full Text] [Related]
15. A 25-gene panel predicting the benefits of immunotherapy in head and neck squamous cell carcinoma.
Huang Y; Liao J; Liang F; Lin P; Wu S; Ye Y; Gao M; Chen R; Zeng H; Yin X; Jiang Y; Ouyang N; Han P; Huang X
Int Immunopharmacol; 2022 Sep; 110():108846. PubMed ID: 35816946
[TBL] [Abstract][Full Text] [Related]
16. PI3K pathway mutation predicts an activated immune microenvironment and better immunotherapeutic efficacy in head and neck squamous cell carcinoma.
Wang L; Chen K; Weng S; Xu H; Ren Y; Cheng Q; Luo P; Zhang J; Liu Z; Han X
World J Surg Oncol; 2023 Mar; 21(1):72. PubMed ID: 36864522
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-to-mesenchymal transition is a prognostic marker for patient outcome in advanced stage HNSCC patients treated with chemoradiotherapy.
van der Heijden M; Essers PBM; Verhagen CVM; Willems SM; Sanders J; de Roest RH; Vossen DM; Leemans CR; Verheij M; Brakenhoff RH; van den Brekel MWM; Vens C
Radiother Oncol; 2020 Jun; 147():186-194. PubMed ID: 32413532
[TBL] [Abstract][Full Text] [Related]
18. Establishment and validation of immune microenvironmental gene signatures for predicting prognosis in patients with head and neck squamous cell carcinoma.
Wang J; Tian Y; Zhu G; Li Z; Wu Z; Wei G; Zhuang L; Li Z; Chen X; Zhang X; Zheng J; Cai G
Int Immunopharmacol; 2021 Aug; 97():107817. PubMed ID: 34091115
[TBL] [Abstract][Full Text] [Related]
19. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Novel Epithelial-Mesenchymal Transition Gene Signature Predicting Survival in Patients With HNSCC.
Xin W; Zhao C; Jiang L; Pei D; Zhao L; Zhang C
Pathol Oncol Res; 2021; 27():585192. PubMed ID: 34257533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
